Article Text

PDF
Concise report
Secukinumab efficacy in anti-TNF-naive and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 Study
  1. Joachim Sieper1,
  2. Atul Deodhar2,
  3. Helena Marzo-Ortega3,
  4. Jacob A Aelion4,
  5. Ricardo Blanco5,
  6. Tseng Jui-Cheng6,
  7. Mats Andersson7,
  8. Brian Porter8,
  9. Hanno B Richards7
  10. on behalf of the MEASURE 2 Study Group
  1. 1Charité University Medicine Berlin, Berlin, Germany
  2. 2Oregon Health & Science University, Portland, Oregon, USA
  3. 3NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust and Leeds Institute for Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK
  4. 4Arthritis Clinic, Jackson, Tennessee, USA
  5. 5Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
  6. 6Kaohsiung Veterans General Hospital, Kaohsiung City, Taiwan
  7. 7Novartis Pharma AG, Basel, Switzerland
  8. 8Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA
  1. Correspondence to Professor Joachim Sieper, Medical Department I, Rheumatology, Campus Benjamin Franklin, Charité Universitätsmedizin Berlin, Hindenburgdamm 30, Berlin 12203, Germany; joachim.sieper{at}charite.de

Abstract

Background There is significant unmet need in patients with ankylosing spondylitis (AS) who have inadequate response or intolerance to anti-tumour necrosis factor (TNF) treatment. Secukinumab, an anti-interleukin-17A monoclonal antibody, significantly improved signs and symptoms of AS in the MEASURE 2 study (NCT01649375).

Methods Subjects with active AS (N=219) received secukinumab (150 or 75 mg) or placebo at baseline, weeks 1, 2, 3 and 4, and every 4 weeks thereafter. Randomisation was stratified by prior anti-TNF use: anti-TNF-naive or inadequate response/intolerance to one anti-TNF (anti-TNF-IR). The primary endpoint was Assessment of SpondyloArthritis International Society criteria (ASAS) 20 at week 16.

Results At week 16, 68.2% of anti-TNF-naive subjects treated with secukinumab 150 mg achieved ASAS20 compared with 31.1% treated with placebo (p<0.001). In the anti-TNF-IR group, 50.0% of subjects treated with secukinumab 150 mg achieved an ASAS20 response compared with 24.1% treated with placebo (p<0.05). Numerically greater improvements were observed with secukinumab than with placebo for most secondary endpoints. Clinical responses were sustained through week 52.

Conclusions Secukinumab 150 mg provided sustained improvements in signs and symptoms of AS in anti-TNF-naive and anti-TNF-IR subjects through 52 weeks of therapy.

Trial registration number NCT01649375.

  • Anti-TNF
  • Ankylosing Spondylitis
  • Treatment

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.